14,290 Shares in Medtronic PLC $MDT Purchased by Stance Capital LLC

Stance Capital LLC acquired a new stake in Medtronic PLC (NYSE:MDT) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 14,290 shares of the medical technology company’s stock, valued at approximately $1,361,000.

A number of other large investors also recently bought and sold shares of the stock. Advisory Services Network LLC increased its position in shares of Medtronic by 4.5% during the third quarter. Advisory Services Network LLC now owns 79,432 shares of the medical technology company’s stock valued at $7,565,000 after acquiring an additional 3,400 shares during the last quarter. Financial Engines Advisors L.L.C. boosted its position in shares of Medtronic by 19.6% during the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,928 shares of the medical technology company’s stock worth $279,000 after purchasing an additional 479 shares during the period. Morningstar Investment Management LLC increased its holdings in Medtronic by 97.7% in the 3rd quarter. Morningstar Investment Management LLC now owns 44,991 shares of the medical technology company’s stock valued at $4,285,000 after purchasing an additional 22,229 shares during the last quarter. NewEdge Advisors LLC raised its position in Medtronic by 47.7% in the third quarter. NewEdge Advisors LLC now owns 201,108 shares of the medical technology company’s stock valued at $19,154,000 after purchasing an additional 64,905 shares during the period. Finally, Armistice Capital LLC lifted its stake in Medtronic by 0.5% during the third quarter. Armistice Capital LLC now owns 265,257 shares of the medical technology company’s stock worth $25,263,000 after purchasing an additional 1,257 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.26% of the company’s stock.

Medtronic Stock Up 0.3%

Shares of NYSE MDT opened at $88.50 on Wednesday. The stock has a market cap of $113.62 billion, a P/E ratio of 24.65, a PEG ratio of 2.26 and a beta of 0.71. The business’s fifty day simple moving average is $97.54 and its 200-day simple moving average is $96.85. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same period in the previous year, the firm posted $1.38 EPS. Medtronic’s revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.2%. Medtronic’s payout ratio is currently 79.11%.

Analysts Set New Price Targets

MDT has been the subject of a number of research reports. Truist Financial dropped their price objective on Medtronic from $107.00 to $103.00 and set a “hold” rating for the company in a research note on Wednesday, February 18th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Wells Fargo & Company assumed coverage on Medtronic in a report on Friday, January 30th. They set an “overweight” rating and a $114.00 target price for the company. William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. Finally, UBS Group reiterated a “neutral” rating and set a $104.00 price target on shares of Medtronic in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $110.74.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).